24/7 Market News Snapshot 06 August, 2025 – Prothena Corporation plc Ordinary Shares (NASDAQ:PRTA)

August 6, 2025

DENVER, Colo., 06 August, 2025 (www.247marketnews.com) – (NASDAQ:PRTA) are discussed in this article.
Prothena Corporation plc (NASDAQ:PRTA) is experiencing significant momentum with its stock price climbing to $7.844, marking an impressive rise of 11.58% from a previous close of $7.030. This robust trading performance is underpinned by a volume of 2.27 million shares, indicative of heightened investor interest and potential for a breakout. Investors are encouraged to observe key support levels around $7.00 and resistance near $8.00 as the market reacts and assesses future trends.

In a pivotal move, Prothena has announced that Novo Nordisk will advance coramitug, a first-in-class amyloid-depleting antibody, into a Phase 3 clinical trial program targeting amyloid transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM). This decision, confirmed during Novo Nordisk’s recent earnings call, aligns with Prothena’s commitment to addressing the critical medical needs of patients suffering from this often fatal condition. Dr. Gene Kinney, Prothena’s President and CEO, expressed optimism regarding this advancement and the essential role coramitug can play in enhancing patient outcomes.

Under the terms of their licensing agreement, Prothena stands to benefit from up to $1.2 billion in potential milestone payments tied to the clinical success and commercialization of coramitug, including a recent upfront payment of $100 million. The company remains poised to receive additional clinical milestone payments following the successful enrollment criteria in the anticipated Phase 3 trial.

Coramitug, previously designated as PRX004, has shown promising preclinical and earlier clinical outcomes by specifically targeting and removing amyloid deposits while preserving normal protein structures. Prothena is committed to pioneering breakthroughs in the fields of neurodegenerative and rare diseases, continuing to innovate pathways that can transform patient lives.

Related news for (PRTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.